Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HLA B7 antibody

HLA B7 Reactivity: Human, Non-Human Primate FACS Host: Mouse Monoclonal BB7-1 unconjugated
Catalog No. ABIN1027673
  • Target See all HLA B7 Antibodies
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Reactivity
    • 13
    • 3
    • 2
    • 2
    • 1
    Human, Non-Human Primate
    Host
    • 11
    • 2
    Mouse
    Clonality
    • 11
    • 2
    Monoclonal
    Conjugate
    • 7
    • 4
    • 2
    This HLA B7 antibody is un-conjugated
    Application
    • 9
    • 3
    • 2
    • 1
    • 1
    Flow Cytometry (FACS)
    Specificity
    The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
    Cross-Reactivity (Details)
    Human, Non-Human Primates
    Purification
    Purified by protein-A affinity chromatography.
    Purity
    > 95 % (by SDS-PAGE)
    Immunogen
    Papain solubilised HLA-A2, B7
    Clone
    BB7-1
    Isotype
    IgG1
    Top Product
    Discover our top product HLA B7 Primary Antibody
  • Application Notes
    Flow cytometry: Recommended dilution: 1-4 μg/mL.
    Restrictions
    For Research Use only
  • Concentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handling Advice
    Do not freeze.
    Storage
    4 °C
    Storage Comment
    Store at 2-8°C. Do not freeze.
  • Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

    de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

    Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

    Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

    Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

  • Target
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Alternative Name
    HLA-B7 (HLA B7 Products)
    Synonyms
    AS antibody, HLAB antibody, SPDA1 antibody, major histocompatibility complex, class I, B antibody, HLA-B antibody
    Background
    HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.
    Pathways
    Human Leukocyte Antigen (HLA) in Adaptive Immune Response
You are here:
Support